SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-24-049437
Filing Date
2024-04-29
Accepted
2024-04-29 07:15:25
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A final_2024_defa14a.htm DEFA14A 20059
2 COURTESY COPY OF FINAL_2024_DEFA14A omga-final_2024_defa14a.pdf DEFA14A 7678668
3 GRAPHIC img88220684_0.jpg GRAPHIC 829552
4 GRAPHIC img88220684_1.jpg GRAPHIC 1054112
  Complete submission text file 0000950170-24-049437.txt   13124332
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40657 | Film No.: 24886577
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)